Profile for Kalkunte Srivenugopal, PhD

Kalkunte Srivenugopal

Kalkunte Srivenugopal, PhD

  • Professor Pharmaceutical Sci Amarillo
Office Phone: 806-414-9612
Mail Address: 1406 S Coulter St
Amarillo TX 79106-1786


Kalkunte S. Srivenugopal, PhD (Venu) is a tenured Professor in the Department of Biomedical Sciences at Texas Tech University Health Sciences Center School of Pharmacy. He joined in September 2002. Dr. Venu received his Ph.D. in Biochemistry from the Indian Institute of Science, Bangalore, India in 1981. Following postdoctoral training at the University of Washington, , he held faculty positions at the Rosalind Franklin University of Medicine and science, University of Medicine and Dentistry of New Jersey and the University of Texas M.D. Anderson Cancer Center before joining the Texas Tech HSC. Dr. Srivenugopal’s research interests include the anticancer drug resistance focusing on the DNA-repair O6-methylguanine-DNA methyltransferase (MGMT), redox stress in cancers and regulation of p53 function. He has been funded in the past by the American Cancer Society, NIH (R29, RO1 and RO3 grants) and currently from the Cancer Prevention and Research Institute of Texas.

Research Interests

Anticancer drug resistance
O6-methylguanine-DNA methyltransferase (MGMT) and MGMT inhibitors for cancer therapy
Redox stress in cancers and exploitation for therapy
Cell cycle
p53 tumor suppressor
Posttranslational modifications
DNA topoisomerases
DNA replication licensing

Selected Publications:

  • Srivenugopal KS. A conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care. Oncotarget4:504-530.
  • Srivenugopal KS. Biochemical mechanism of caffeic acid phenylethyl ester (CAPE) selective toxicity towards melanoma cell lines. Chemico-Biological Interactions188(1):1-14.
  • Srivenugopal KS. Degradation of NF-κB, p53 and other regulatory redox-sensitive proteins by thiol-conjugating and -nitrosylating drugs in human tumor cells. Carcinogenesis34:990-1000.
  • Srivenugopal KS. MGMT inhibition restores ERα functional sensitivity to antiestrogen therapy. Molecular Medicine18:913-929.
  • Yusuf M, Chuang T, Bhat G, Srivenugopal KS, . Cys-141 glutathionylation of human p53: Studies using specific polyclonal antibodies in cancer samples and cell lines. Free Radical Biology and Medicine 2010;49:908-917.